Compare Carlyle Group Inc (CG) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Tempus AI — how do they compare? Carlyle Group Inc trades at $44.23 (market cap $16.37B), while Tempus AI trades at $59.09 (market cap $10.54B). The key difference: Carlyle Group Inc is the larger of the two by market cap, and Carlyle Group Inc pays a 3.08% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| CG | TEM | |
|---|---|---|
Market Cap | $16.37B | $10.54B |
Sector | Financials | Broad Market / Factor |
52-Week High | $69.35 | $103.25 |
52-Week Low | $40.52 | $42.37 |
Dividend Yield | 3.08% | — |
Enterprise Value | — | $11.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $44.14, down 1.27% on the day, with a neutral technical signal and bearish moving averages. The company reported revenue of $3.21B and net income of $808.70M for 2025, with a P/E ratio of 30.24. Recent developments include the acquisition of a majority stake in MAI Capital Management and the upcoming Q2 2026 earnings release on August 5, 2026.
The outlook is mixed, with analyst consensus leaning bullish (53.84% Buy) and a price target of $58.57 implying significant upside. However, risks include volatile cash flows from operations, recent earnings misses, and a high valuation. The stock's performance hinges on successful execution of growth initiatives and improved earnings consistency.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
